STANFORD, CA – April 24, 2024 – A protein long celebrated for its life-sustaining role in stimulating red blood cell production has now been unmasked as a critical, unexpected antagonist in the fight against cancer. New research published today in Science reveals that erythropoietin (EPO), identified nearly four decades ago, plays a surprising and pivotal role in suppressing the immune system’s ability to combat tumors, particularly those considered "cold" and resistant to existing immunotherapies. This groundbreaking discovery could unlock a new frontier in cancer treatment, offering hope for patients with currently untreatable malignancies.
The study, led by Dr. Edgar Engleman, a professor of pathology and medicine at Stanford University, and Dr. David Kung-Chun Chiu, a basic life research scientist, demonstrates that blocking EPO’s activity can transform previously immune-resistant liver tumors in mice into "hot" tumors, teeming with cancer-fighting immune cells. When this blockade was combined with an immunotherapy that further activates these immune cells, the treatment led to the complete regression of existing liver tumors in most mice, with treated animals surviving for the entire duration of the experiment. In stark contrast, control animals succumbed to the disease within weeks.
"This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer," stated Dr. Engleman, the senior author of the research. "I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials." The findings not only shed light on a previously unknown mechanism of immune evasion but also provide a compelling rationale for a novel therapeutic approach that could significantly broaden the efficacy of immunotherapy across a wide spectrum of human cancers.
The Unveiling of EPO’s Dual Nature: A Chronological Revelation
The journey to understanding EPO’s complex role in cancer is a story spanning decades, marked by both its celebrated use in medicine and a puzzling, persistent shadow.
A Legacy of Life-Saving Function:
For nearly 40 years, erythropoietin has been primarily recognized for its vital function in hematopoiesis – the process of red blood cell formation. Produced predominantly by the kidneys, EPO acts as a hormone, signaling the bone marrow to produce more red blood cells, thereby combating anemia and ensuring adequate oxygen delivery throughout the body. Its therapeutic application, particularly in patients with kidney failure or those undergoing chemotherapy, has saved countless lives and improved quality of life.
The First Hint of Trouble: A Puzzling Correlation:
However, as early as the turn of the millennium, clinical observations began to cast a perplexing shadow over EPO’s otherwise pristine reputation. Studies involving cancer patients suffering from chemotherapy-induced anemia, who were treated with recombinant human EPO to stimulate red blood cell formation, started to reveal an alarming trend: instead of merely alleviating anemia, EPO appeared to accelerate tumor growth and worsen patient outcomes in some cases. This correlation was sufficiently striking that, in 2007, the U.S. Food and Drug Administration (FDA) mandated a "black box warning" on EPO-stimulating agents, cautioning against their use in people with cancers due to the observed tumor progression.
At the time, the precise mechanism behind this detrimental effect remained elusive. Researchers could only surmise that EPO might directly stimulate cancer cell proliferation, perhaps through receptors present on tumor cells. The connection to the immune system, however, was never definitively made, leaving a significant gap in the scientific understanding of this critical phenomenon. "Those old reports showed clearly that the more EPO or EPOR [EPO receptor] there was in tumors, the worse off the patients were," Dr. Engleman recalled. "But the connection between EPO and cancer immunity was never made until now." The prevailing dogma of EPO solely as a red blood cell growth factor proved to be a powerful intellectual barrier, making it challenging for the scientific community, and even the researchers themselves, to consider alternative, more complex roles. "In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, because EPO is so well established as a red blood cell growth factor," Engleman added.
The Modern Investigation: Unraveling the Immunosuppressive Link:
The current breakthrough stems from a meticulous and innovative research program spearheaded by Dr. David Kung-Chun Chiu. Dr. Chiu dedicated himself to developing and studying advanced genome editing techniques to create sophisticated mouse models of liver cancer. These models were designed to precisely recapitulate specific mutations, histological features, and responses to approved therapies observed in various subtypes of human liver cancers. Tumor formation was induced either by injecting a combination of DNA encoding proteins associated with liver cancer into the animals’ tail vein or by directly implanting liver cancer cells into the animals’ livers, allowing for a comprehensive study of tumor development and treatment response.
The team’s initial focus was on understanding the efficacy of a common immunotherapy that targets PD-1, a molecule on immune cells called T cells. Anti-PD-1 therapies, such as Keytruda, work by blocking cancer cells’ ability to "turn off" T cells, thereby unleashing the immune system against the tumor. While these therapies have revolutionized the treatment of certain cancers like melanoma and Hodgkin’s lymphoma, a vast majority of tumors, including most liver, pancreas, colon, breast, and prostate cancers, remain stubbornly resistant.
It was during these investigations into "cold" (immune-resistant) versus "hot" (immune-inflamed) tumors that the unexpected role of EPO began to emerge. The researchers observed that the cold tumors, which were largely ignored by the immune system and unresponsive to anti-PD-1 treatment, displayed conspicuously elevated levels of EPO. This discovery ignited a new line of inquiry, leading the team to connect decades of perplexing clinical observations with a novel, critical understanding of EPO’s role in cancer immunity.
Supporting Data: From Mouse Models to Molecular Mechanisms
The journey from initial observation to mechanistic understanding involved a series of rigorously designed experiments that collectively painted a clear picture of EPO’s immunosuppressive function.
Elucidating the "Cold" vs. "Hot" Tumor Landscape:
The research utilized a sophisticated array of mouse models, each engineered with specific genetic mutations to mimic the diverse landscape of human liver cancers. This approach allowed the scientists to create both "cold" and "hot" tumor environments within the same experimental framework.
- "Cold" Tumors: These tumors, characterized by a scarcity of immune cells, particularly T cells, in their microenvironment, proved resistant to anti-PD-1 therapy. This mirrors the clinical reality where many aggressive cancers evade immune detection and therapy. The researchers meticulously documented the lack of T cell infiltration and the resulting immune privilege of these cold tumors.
- "Hot" Tumors: In contrast, other genetic mutations led to the development of "inflamed" or "hot" tumors, which were replete with T cells. These tumors were highly sensitive to anti-PD-1 treatment, demonstrating robust T cell activation and subsequent cancer attack, underscoring the potential of immunotherapy when the immune system is properly engaged.
The Unexpected Rise of EPO in Cold Tumors:
A pivotal observation was the significantly elevated levels of EPO detected in the cold tumors compared to their hot counterparts. This increase was hypothesized to be a consequence of the oxygen-poor microenvironment – a condition known as hypoxia – commonly prevalent within these immune-resistant tumors. Hypoxia is a well-known inducer of various proteins in cancer cells, including those that typically ramp up EPO production to create more red blood cells, an adaptive response to combat low oxygen levels. However, as Dr. Engleman noted, "Hypoxia in tumors has been studied for decades. It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor." This highlighted the scientific blind spot that the team meticulously worked to overcome.
Validating the Human Connection:
To bolster the relevance of their mouse findings to human oncology, the researchers cross-referenced their observations with existing patient databases. This analysis confirmed a strong correlation between elevated levels of EPO and poorer survival rates in human patients with a variety of cancers, including those of the liver, kidney, breast, colon, and skin. This crucial piece of supporting data provided compelling evidence that EPO’s newly identified role was not merely a murine phenomenon but likely a conserved mechanism in human disease.
Genetic Manipulation: A Definitive Link:
The research then moved to directly manipulate EPO production in the tumor models, yielding definitive proof of its immunosuppressive role:
- Turning Cold to Hot: When tumor cells that typically led to cold tumors were genetically modified to be unable to produce EPO, they astonishingly transformed into hot tumors. These previously immune-resistant tumors now showed significant immune cell infiltration and became sensitive to anti-PD-1 therapy.
- Turning Hot to Resistant: Conversely, hot tumors, which were normally eradicated by the immune system and responsive to anti-PD-1, thrived and evaded immune attack when they were engineered to produce elevated levels of EPO. This provided a direct cause-and-effect relationship between EPO and immune evasion.
Unraveling the Cellular Mechanism: EPO-Macrophage Crosstalk:
Further exhaustive research delved into the precise cellular and molecular mechanisms underlying EPO’s immunosuppressive effects. The team discovered that in cold tumors, the tumor cells themselves produce and secrete EPO. This secreted EPO then acts on nearby immune cells, specifically macrophages, by binding to EPO receptors (EPOR) on their surface. Upon EPO binding, these macrophages undergo a phenotypic switch, adopting an immunosuppressive role. In this altered state, the macrophages actively "shoo away" cancer-killing T cells from the tumor microenvironment and dampen their cytotoxic activity, effectively shielding the tumor from immune attack. This elegant yet insidious mechanism provides a clear pathway by which EPO orchestrates immune evasion.
The Power of Combination Therapy:
The most striking evidence of EPO’s critical role, and the therapeutic potential of targeting it, came from experiments combining EPO pathway blockade with anti-PD-1 immunotherapy.
- In control groups, mice with cold liver tumors treated with either a placebo or anti-PD-1 alone succumbed to their disease within eight weeks of tumor induction.
- In contrast, 40% of mice whose macrophages were genetically engineered to lack the EPO receptor (thereby blocking EPO signaling) lived for the full 18-week duration of the experiment, demonstrating a significant standalone benefit.
- However, the most dramatic outcome occurred when anti-PD-1 treatment was administered to mice lacking the EPO receptor: all animals lived for the duration of the experiment, achieving complete tumor regression.
"It’s simple," Dr. Engleman emphasized. "If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment." This synergistic effect underscores the potential of this discovery to revolutionize treatment for previously intractable cancers.
Official Responses and Recognition
The publication of these findings in Science, one of the world’s most prestigious scientific journals, marks a significant moment in cancer research.
From the Lead Researchers:
Dr. Engleman’s enthusiasm for the discovery is palpable. His conviction that this represents a "fundamental breakthrough" speaks to the depth of the mechanistic insight and the potential breadth of its therapeutic application. His hope for rapid translation to human trials reflects the urgency and unmet need in oncology, particularly for patients with "cold" tumors. The journey to this discovery, as he noted, was challenging, requiring the team to overcome decades of established scientific understanding regarding EPO’s primary function. This persistence and willingness to challenge dogma are hallmarks of truly transformative research.
Dr. Chiu, as the lead author, played an indispensable role in the meticulous development of the advanced mouse models and the execution of the intricate genetic and immunological experiments that underpinned the discovery. His innovative approach to modeling human liver cancers was crucial for revealing EPO’s unexpected function.
Historical Context Reconsidered:
The research provides a compelling, mechanistic explanation for the puzzling clinical observations that led to the FDA’s 2007 black box warning on EPO-stimulating agents for cancer patients. What was once an unexplained correlation between EPO administration and accelerated tumor growth can now be understood as EPO’s direct involvement in fostering an immunosuppressive tumor microenvironment. This retrospective clarity validates previous clinical concerns and highlights the importance of continued basic research in understanding complex biological interactions.
Broader Scientific Impact:
The scientific community is expected to greet these findings with significant interest. The work not only identifies a novel therapeutic target but also deepens the understanding of immune evasion strategies employed by tumors, particularly the role of hypoxia and macrophage polarization. This will likely stimulate further research into EPO signaling pathways in various cancer types and contribute to a more nuanced understanding of the tumor microenvironment.
Funding and Collaborations:
The study received substantial support from the National Institutes of Health (NIH), with grants including R01CA262361, P01CA244114, U54CA2745115, and P01HL149626. This federal funding underscores the national commitment to advancing cancer research. Additionally, researchers from the New York Blood Center and the pharmaceutical company ImmunEdge Inc. contributed to the research, highlighting the collaborative nature of modern scientific discovery. Notably, Dr. Chiu is a cofounder of ImmunEdge Inc., and Dr. Engleman is a founder, shareholder, and board member of the company. Both researchers are also Stanford-affiliated inventors of a pending patent (PCT/US2023/063997) entitled "EPO receptor agonists and antagonists," indicating a clear path toward potential therapeutic development based on these findings.
Implications: A New Era for Immunotherapy and Cold Tumors
The implications of this discovery are profound, potentially ushering in a new era for cancer immunotherapy and offering tangible hope for patients with previously intractable cancers.
Transforming the Treatment Landscape for "Cold" Tumors:
Perhaps the most significant implication is the potential to transform the treatment paradigm for "cold" tumors. These malignancies, which constitute a large proportion of human cancers (including liver, pancreas, colon, breast, and prostate cancers), have historically been resistant to immune checkpoint inhibitors like anti-PD-1 therapy due to their inherent lack of immune cell infiltration. By demonstrating that blocking EPO signaling can "heat up" these cold tumors, making them susceptible to immunotherapy, this research offers a powerful strategy to extend the benefits of immune-based treatments to a much broader patient population. It fundamentally redefines how we might approach these challenging diseases.
Novel Therapeutic Strategies:
The research proposes several clear therapeutic avenues for clinical development:
- Direct EPO Targeting: One approach involves non-specifically targeting the EPO protein itself. While this could potentially lead to side effects such as anemia (given EPO’s role in red blood cell production), Dr. Engleman speculates that this might be an acceptable trade-off for an effective cancer therapy, especially for aggressive malignancies with limited treatment options. The development of EPO antagonists or antibodies that neutralize EPO could be pursued.
- Targeting Macrophage EPO Receptors: A more refined and potentially less toxic strategy involves selectively blocking the EPO receptors (EPOR) specifically on the surfaces of macrophages within the tumor microenvironment. This approach would aim to prevent macrophages from adopting their immunosuppressive role without interfering with systemic EPO function in red blood cell production. Such a targeted therapy could significantly reduce off-target effects. The involvement of ImmunEdge Inc. and the pending patent suggest active efforts in drug discovery based on these mechanisms.
Deeper Understanding of the Tumor Microenvironment:
Beyond direct therapeutic applications, this discovery significantly enhances our understanding of the complex interplay within the tumor microenvironment. It highlights the critical role of hypoxia, a common feature of many solid tumors, in driving immune evasion through unexpected pathways. It also sheds light on the plasticity of macrophages, demonstrating how they can be reprogrammed from an anti-tumor to a pro-tumor, immunosuppressive phenotype under the influence of factors like EPO. This deeper understanding can inform the development of other microenvironment-modulating therapies.
Revisiting Existing Knowledge:
The study serves as a powerful reminder that biological molecules often have multiple, context-dependent functions. EPO, long considered a benevolent red blood cell growth factor, is now revealed to possess a "dark side" in the context of cancer. This encourages scientists to revisit other well-characterized proteins and pathways, re-evaluating their roles within the complex and often contradictory biological landscape of cancer.
Future Research and Clinical Trials:
The immediate next steps will undoubtedly involve rigorous preclinical validation and the eventual translation of these findings into human clinical trials. Identifying specific biomarkers to predict patient response and stratify patients for EPO-targeted therapies will be crucial. Furthermore, future research will explore whether EPO plays similar immunosuppressive roles in other types of cancer beyond those initially studied and whether its blockade can enhance other forms of immunotherapy or conventional treatments.
"I continue to be amazed by this finding," Dr. Engleman reiterated. "Not every tumor is going to respond in the same way, but I’m very optimistic that this discovery will lead to powerful new cancer therapies." This optimism is well-founded, given the clarity of the mechanism, the dramatic preclinical results, and the unmet need in treating "cold" tumors. The revelation of EPO’s hidden role in cancer immunity stands as a testament to the enduring power of scientific inquiry to challenge assumptions and uncover truths that can fundamentally alter the course of human health.
About the Author
